TD Cowen Increases ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $37.00

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its target price hoisted by investment analysts at TD Cowen from $35.00 to $37.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. TD Cowen’s price target indicates a potential upside of 50.65% from the company’s current price.

Several other equities analysts have also recently issued reports on ACAD. Oppenheimer reiterated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Friday, February 6th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a report on Monday, December 29th. UBS Group upped their target price on ACADIA Pharmaceuticals from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Citigroup upped their price objective on shares of ACADIA Pharmaceuticals from $33.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Finally, Needham & Company LLC restated a “buy” rating and set a $34.00 price target on shares of ACADIA Pharmaceuticals in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, ACADIA Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.74.

ACADIA Pharmaceuticals Stock Performance

NASDAQ ACAD opened at $24.56 on Thursday. The firm has a market capitalization of $4.16 billion, a P/E ratio of 10.72, a PEG ratio of 8.72 and a beta of 0.66. The stock has a 50-day simple moving average of $25.53 and a two-hundred day simple moving average of $24.45. ACADIA Pharmaceuticals has a fifty-two week low of $13.40 and a fifty-two week high of $28.35.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its earnings results on Wednesday, February 25th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping the consensus estimate of $0.12 by $1.48. ACADIA Pharmaceuticals had a return on equity of 13.96% and a net margin of 36.49%.The firm had revenue of $298.00 million for the quarter, compared to analyst estimates of $292.54 million. During the same period last year, the company earned $0.86 earnings per share. ACADIA Pharmaceuticals’s revenue for the quarter was up 9.4% compared to the same quarter last year. As a group, analysts forecast that ACADIA Pharmaceuticals will post 0.7 earnings per share for the current year.

Insider Activity at ACADIA Pharmaceuticals

In related news, EVP Jennifer J. Rhodes sold 6,950 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $23.38, for a total value of $162,491.00. Following the transaction, the executive vice president directly owned 7,609 shares in the company, valued at approximately $177,898.42. This represents a 47.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 26.50% of the company’s stock.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Braidwell LP acquired a new position in shares of ACADIA Pharmaceuticals in the 3rd quarter worth approximately $50,760,000. Marshall Wace LLP lifted its position in shares of ACADIA Pharmaceuticals by 496.2% during the second quarter. Marshall Wace LLP now owns 1,969,711 shares of the biopharmaceutical company’s stock worth $42,487,000 after purchasing an additional 1,639,315 shares in the last quarter. Norges Bank purchased a new stake in ACADIA Pharmaceuticals during the 4th quarter worth approximately $40,266,000. Millennium Management LLC grew its stake in shares of ACADIA Pharmaceuticals by 2,052.1% in the third quarter. Millennium Management LLC now owns 1,483,235 shares of the biopharmaceutical company’s stock worth $31,652,000 after acquiring an additional 1,414,315 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in shares of ACADIA Pharmaceuticals by 390.1% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,648,864 shares of the biopharmaceutical company’s stock valued at $35,187,000 after acquiring an additional 1,312,426 shares in the last quarter. 96.71% of the stock is currently owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals News Summary

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Q4 beat and upgraded 2026 revenue outlook — ACAD reported stronger-than-expected Q4 results (EPS beat) and a milestone year with >$1B in revenue, and guided 2026 revenue to $1.22B–$1.28B, driven by NUPLAZID and DAYBUE. This underpins growth expectations for the company. Acadia Reports Q4 & Full Year 2025 Results
• Positive Sentiment: Analyst price-target upgrades — Several firms raised targets after the quarter (TD Cowen to $37 and Citizens JMP to $35), reflecting confidence in commercial momentum for DAYBUE and NUPLAZID. Benzinga coverage of analyst moves
• Neutral Sentiment: Minor analyst downtick but still constructive — Royal Bank of Canada trimmed its target to $30 but keeps an “outperform” view; this is a modest adjustment rather than a directional reversal. Benzinga: RBC target change
• Neutral Sentiment: Short-interest data appears anomalous — February short-interest entries show 0 shares / NaN increases and 0.0 days-to-cover, indicating a data/reporting glitch rather than a real shift in short positioning.
• Negative Sentiment: Analyst EPS cuts from HC Wainwright — HC Wainwright trimmed Q3 and Q4 2026 EPS estimates (Q3: $0.16 from $0.24; Q4: $0.23 from $0.27), which can pressure near-term expectations despite a buy rating and $37 target.
• Negative Sentiment: Some sell-side caution — Stifel lowered its target to $24 and moved to a “hold,” a more conservative stance that adds selling pressure versus the upgrades. Benzinga: Stifel target change
• Negative Sentiment: Pipeline/regulatory and sales nuances — Coverage noted a sales miss in places and an EU setback for trofinetide that clouds parts of the growth narrative even as core brands accelerate. Zacks: Q4 recap and trofinetide outlook

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.